Multidimensional assessment: Pain and palliative care

Cancer Pain: Assessment and Management, Second Edition

Volumn , Issue , 2009, Pages 105-129

  O’Leary, Norma ^a   Stone, Carol ^b   Lawlor, Peter G ^c,d  

^a Marie Curie Hospice   (United Kingdom)

^b Palliative Medicine   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857412763     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511642357.007     Document Type: Chapter

References (274)

1. World Health Organization. Cancer pain relief and palliative care. WHO Expert Committee. World Health Organization- Technical Report Series, 804. Geneva: World Health Organization, 1990, pp 1-75.
2. Vainio A, Auvinen A. Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage 12:310, 1996.
3. Grond S, Zech D, Diefenbach C, Bischoff A. Prevalence and pattern of symptoms inpatients with cancer pain: aprospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage 9:372-82, 1994.
4. Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 8:175-9, 2000.
5. Potter J, Hami F, Bryan T, Quigley C. Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med 17:310-14, 2003.
6. Fainsinger R, Miller MJ, Bruera E, et al. Symptom control during the last week of life on a palliative care unit. J Palliat Care 7:5-11, 1991.
7. Zech DF, Grond S, Lynch J, et al. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 63:65-76, 1995.
8. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 274:1870-3, 1995.
9. Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 93:247-57, 2001.
10. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330:592-6, 1994.
11. Azevedo São Leão Ferreira K, Kimura M, Jacobsen Teixeira M. The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it? Support Care Cancer 14:1086-9, 2006.
12. Anderson KO, Mendoza TR, Valero V, et al. Minority cancer patients and their providers: pain management attitudes and practice. Cancer 88:1929-38, 2000.
13. Sloan PA, Donnelly MB, Schwartz RW, Sloan DA. Cancer pain assessment and management by housestaff. Pain 67:475-81, 1996.
14. Sloan PA, Vanderveer BL, Snapp JS, et al. Cancer pain assessment and management recommendations by hospice nurses. University of Kentucky, Lexington, Kentucky. J Pain Symptom Manage 18:103-10, 1999.
15. Caraceni A, Cherny N, Fainsinger R, et al. Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage 23:239-55, 2002.
16. Bruera E, Kim HN. Cancer pain. JAMA 290:2476-9, 2003.
17. Portenoy R., Lesage P. Management of cancer pain. Lancet 353:1695-700, 1999.
18. Bruera E, Lawlor P. Cancer pain management. Acta Anaes- thesiol Scand 41:146-53, 1997.
19. Melzack R, Casey KL. Sensory, motivational and central control determinants of pain: a new conceptual model. In: Kenshalo D, ed. The skin senses. Springfield, IL: Charles C Thomas, 1968, pp 423-39.
20. Ahles TA, Blanchard EB, Ruckdeschel JC. The multidimensional nature of cancer-related pain. Pain 17:277-88, 1983.
21. Merskey H, Bogduk N. Classification of chronic pain. Seattle: IASP Press, 1994, p 210.
22. Price DD, Harkins SW, Baker C. Sensory-affective relationships among different types of clinical and experimental pain. Pain 28:297-307, 1987.
23. Bond MR. Psychological issues in cancer and non-cancer conditions. Acta Anaesthesiol Scand 45:1095-9, 2001.
24. Trask PC. Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy. Health Qual Life Outcomes 2:37, 2004.
25. Detmar SB, Muller MJ, Wever LD, et al. The patient-physician relationship. Patient-physician communication during outpatient palliative treatment visits: an observational study. JAMA 285:1351-7, 2001.
26. Jacox A, Carr DB, Payne R. Pharmacologic management. Clinical practice guidelines: management of cancer pain. Rockville: U.S. Department of Health and Human Services, 1994, pp 39-74.
27. WHO Definition of palliative care. World Health Organization 8-9-2006. Available from: http://www.who.int/cancer/palliative/definition/en.
28. Ingham J, Breitbart W. Epidemiology and clinical features of delirium. In: Portenoy RK, Bruera E, eds. Topics in palliative care. New York: Oxford University Press, 1997, pp 7-19.
29. Friedlander M, Lawlor P, Breitbart W. Delirium in the terminally ill. In: Chochinov HM, Breitbart W, eds. Oxford handbook of psychiatry in palliative medicine, 2nd ed. New York: Oxford University Press, 2008, pp 75-91.
30. Gagnon B, Lawlor P., Mancini IL, et al. The impact of delirium on the circadian distribution of breakthrough analgesia in advanced cancer patients. J Pain Symptom Manage 22:826-33, 2001.
31. Lawlor P., Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 160:786-94, 2000.
32. Minagawa H, Uchitomi Y, Yamawaki S, Ishitani K. Psychiatric morbidity in terminally ill cancer patients. A prospective study. Cancer 78:1131-7, 1996.
33. American Psychiatric Association. Delirium, dementia and amnestic and other cognitive disorders. In: Diagnostic and statistical manual of mental disorders, 4th ed. Washington DC: American Psychiatric Association, 1994, pp 123-33.
34. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-98, 1975.
35. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population- based norms for the Mini-Mental State Examination by age and educational level [see comment]. JAMA 269:2386-91, 1993.
36. Inouye SK. The dilemma of delirium: clinical and research controversies regarding diagnosis and evaluation of delirium in hospitalized elderly medical patients. Am J Med 97:278-88, 1994.
37. Armstrong SC, Cozza KL, Watanabe KS. The misdiagnosis of delirium. Psychosomatics 38:433-9, 1997.
38. Hjermstad M, Loge JH, Kaasa S. Methods for assessment of cognitive failure and delirium in palliative care patients: implications for practice and research. Palliat Med 18:494-50, 2004.
39. Pereira J, Hanson J, Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer 79:835-42, 1997.
40. Goring H, Baldwin R, Marriott A, et al. Validation of short screening tests for depression and cognitive impairment in older medically ill inpatients. Int J Geriatr Psychiatry 19:465-71, 2004.
41. Arsene O, Lassauniere JM. Evaluation of cognitive disorders and screening of delirium in cancer patients receiving morphine. Comparison of the use of the Elementary Test of Concentration, Orientation and Memory (TELECOM) and of the Mini-Mental State Examination (MMSE). Presse Medicale 29:2207-12, 2000.
42. Leonard M, Godfrey A, Silberhorn M, et al. Motion analysis in delirium: a novel method of clarifying motoric subtypes. Neurocase 13:272-7, 2007.
43. de Rooij SE, van Munster BC, Korevaar JC, et al. Delirium subtype identification and the validation of the Delirium Rating Scale-Revised-98 (Dutch version) in hospitalized elderly patients. Int J Geriatr Psychiatry 21:876-8, 2006.
44. Lawlor P, Gagnon B, Mancini I, et al. Phenomenology of delirium and its subtypes in advanced cancer patients: a prospective study. J Palliat Care 14:106, 1998.
45. Coyle N, Breitbart W, Weaver S, Portenoy R. Delirium as a contributing factor to “crescendo” pain: three case reports. J Pain Symptom Manage 9:44-7, 1994.
46. Fainsinger RL, Tapper M, Bruera E. A perspective on the management of delirium in terminally ill patients on a palliative care unit. J Palliat Care 9:4-8, 1993.
47. Lawlor P, Walker P, Bruera E, Mitchell S. Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. J Pain Symptom Manage 13:356-61, 1997.
48. Lawlor P., Fainsinger RL, Bruera ED. Delirium at the end of life: critical issues in clinical practice and research. JAMA 284:2427-9, 2000.
49. Kenne SE, Ohlen J, Jonsson T, Gaston-Johansson F. Coping with recurrent breast cancer: predictors of distressing symptoms and health-related quality of life. J Pain Symptom Manage 34:24-39, 2007.
50. Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer 6:356-64, 1998.
51. Bruera E, Suarez-Almazor M, Velasco A, et al. The assessment of constipation in terminal cancer patients admitted to a palliative care unit: a retrospective review. J Pain Symptom Manage 9:515-19, 1994.
52. Holen JC, Hjermstad MJ, Loge JH, et al. Pain assessment tools: is the content appropriate for use in palliative care? J Pain Symptom Manage 32:567-80, 2006.
53. Portenoy R., Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326-36, 1994.
54. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs 1:373-8, 1978.
55. Bruera E, Kuehn N, Miller MJ, et al. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6-9, 1991.
56. Bruera E. Patient assessment in palliative cancer care. Cancer Treat Rev 22(Suppl A):3-12, 1996.
57. Rees E, Hardy J, Ling J, et al. The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK. Palliat Med 12:75-82, 1998.
58. Nekolaichuk CL, Maguire TO, Suarez-Almazor M, et al. Assessing the reliability of patient, nurse, and family caregiver symptom ratings in hospitalized advanced cancer patients. J Clin Oncol 17:3621-30, 1999.
59. Nekolaichuk CL, Bruera E, Spachynski K, et al. A comparison of patient and proxy symptom assessments in advanced cancer patients. Palliat Med 13:311-23, 1999.
60. Bruera E, Macdonald S. Audit methods: the Edmonton Symptom Assessment System. In: Higginson I, ed. Clinical audit in palliative care. Oxford: Radcliffe Medical Press, 1993, pp 61-77.
61. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton symptom assessment scale. Cancer 88:2164-71, 2000.
62. Modonesi C, Scarpi E, Maltoni M, et al. Impact of palliative care unit admission on symptom control evaluated by the Edmonton symptom assessment system. J Pain Symptom Manage 30:367-73, 2005.
63. Heedman PA, Strang P. Symptom assessment in advanced palliative home care for cancer patients using the ESAS: clinical aspects. Anticancer Res 21:4077-82, 2001.
64. Bradley N, Davis L, Chow E. Symptom distress in patients attending an outpatient palliative radiotherapy clinic. J Pain Symptom Manage 30:123-31, 2005.
65. Pautex S, Berger A, Chatelain C, et al. Symptom assessment in elderly cancer patients receiving palliative care. Crit Rev Oncol Hematol 47:281-6, 2003.
66. Stromgren AS, Groenvold M, Sorensen A, Andersen L. Symptom recognition in advanced cancer. A comparison of nursing records against patient self-rating. Acta Anaesthesiol Scand 45:1080-5, 2001.
67. Chochinov HM, Tataryn D, Clinch JJ, Dudgeon D. Will to live in the terminally ill. Lancet 354:816-19, 1999.
68. Gagnon B, Lawlor P., Mancini I, et al. The impact of delirium on the expression of pain and other symptoms in advanced cancer patients. In: Proceedings of the 9th World Congress of the International Association for the Study of Pain. Seattle: IASP Press, 1999.
69. Kirkova J, Davis MP, Walsh D, et al. Cancer symptom assessment instruments: a systematic review. J Clin Oncol 24:1459-73, 2006.
70. Waldron D, O’Boyle CA, Kearney M, et al. Quality-of-life measurement in advanced cancer: assessing the individual. J Clin Oncol 17:3603-11, 1999.
71. Hanks GW, Forbes K. Opioid responsiveness. Acta Anaesthesiol Scand 41:154-8, 1997.
72. American Joint Committee for Cancer Staging and End Result Reporting. Manual for staging of cancer. Chicago: American Joint Committee, 1977.
73. Paterson AHG. Clinical staging and its prognostic significance. In: Stall B, ed. Pointers to cancer prognosis. Dordrecht: Martinus Nijhoff, 1988, pp 37-48.
74. Bruera E, Macmillan K, Hanson J, MacDonald RN. The Edmonton staging system for cancer pain: preliminary report. Pain 37:203-9, 1989.
75. Bruera E, Schoeller T, Wenk R, et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage 10:348-55, 1995.
76. Fainsinger RL, Nekolaichuk CL, Lawlor P., et al. A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manage 29:224-37, 2005.
77. Nekolaichuk CL, Fainsinger RL, Lawlor PG. A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton Classification System for Cancer Pain. Palliat Med 19:466-76, 2005.
78. Lowe SS, Nekolaichuk CL, Fainsinger RL, Lawlor P. Should the rate of opioid dose escalation be included as a feature in a cancer pain classification system? J Pain Symptom Manage 35:51-7, 2008.
79. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 33:11-23, 1988.
80. Portenoy R., Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 43:273-86, 1990.
81. Cherny NI, Thaler HT, Friedlander-Klar H, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies. Neurology 44:857-61, 1994.
82. Jadad AR, Carroll D, Glynn CJ, et al. Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia. Lancet 339:1367-71, 1992.
83. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118:289-305, 2005.
84. Grond S, Radbruch L, Meuser T, et al. Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain 79:15-20, 1999.
85. McQuay HJ, Jadad AR. Incident pain. Cancer Surv 21:17-24, 1994.
86. Portenoy R., Payne R, Coluzzi P, et al. Oral transmucosal fen- tanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 79:303-12, 1999.
87. Zeppetella G, Ribeiro MDC. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev CD004311, 2006.
88. Portenoy R., Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 41:273-81, 1990.
89. Portenoy R., Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129-34, 1999.
90. Caraceni A, Portenoy R. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. Pain 82:263-74, 1999.
91. Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 18:177-83, 2004.
92. Larue F, Colleau SM, Fontaine A, Brasseur L. Oncologists and primary care physicians’ attitudes toward pain control and morphine prescribing in France. Cancer 76:2375-82, 1995.
93. Warncke T, Breivik H, Vainio A. Treatment of cancer pain in Norway. A questionnaire study. Pain 57:109-16, 1994.
94. Grossman SA. Undertreatment of cancer pain: barriers and remedies. Support Care Cancer 1:74-8, 1993.
95. Ward S., Goldberg N, Miller-McCauley V, et al. Patient- related barriers to management of cancer pain. Pain 52:319-24, 1993.
96. Gunnarsdottir S, Serlin RC, Ward S. Patient-related barriers to pain management: the Icelandic Barriers Questionnaire II. J Pain Symptom Manage 29:273-85, 2005.
97. Gunnarsdottir S, Donovan HS, Serlin RC, et al. Patient-related barriers to pain management: the Barriers Questionnaire II (BQ-II). Pain 99:385-96, 2002.
98. Cherny NJ, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 76:1283-9, 1995.
99. Kochhar R, LeGrand SB, Walsh D, et al. Opioids in cancer pain: common dosing errors. Oncology 17:571-5, 2003.
100. Lawlor P., Bruera E. Side-effects of opioids in chronic pain treatment. Curr Opin Anaesthesiol 11:539-45, 1998.
101. Daeninck PJ, Bruera E. Opioid use in cancer pain. Is a more liberal approach enhancing toxicity? Acta Anaesthesiol Scand 43:924-38, 1999.
102. Hagen N, Swanson R. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies. J Pain Symptom Manage 14:51-8, 1997.
103. Sjogren P, Jonsson T, Jensen NH, et al. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 55:93-7, 1993.
104. Sjogren P, Dragsted L, Christensen CB. Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand 37:780-2, 1993.
105. Ashby M, Fleming B, Wood M, Somogyi A. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J Pain Symptom Manage 14:157-67, 1997.
106. Faura CC, Collins SL, Moore RA, McQuay HJ. Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain 74:43-53, 1998.
107. McQuay HJ, Carroll D, Faura CC, et al. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 48:236-44, 1990.
108. Osborne R, Thompson P, Joel S, et al. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 34:130-8, 1992.
109. Gong QL, Hedner J, Bjorkman R, Hedner T. Morphine- 3-glucuronide may functionally antagonize morphine-6- glucuronide induced antinociception and ventilatory depression in the rat. Pain 48:249-55, 1992.
110. Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide - a potent antagonist of morphine analgesia. Life Sci 47:579-85, 1990.
111. Wright AW, Nocente ML, Smith MT. Hydromorphone-3- glucuronide: biochemical synthesis and preliminary pharmacological evaluation. Life Sci 63:401-11, 1998.
112. Mercadante S. The role of morphine glucuronides in cancer pain. PalliatMed 13:95-104, 1999.
113. Quigley C, Joel S, Patel N, etal. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med 17:185-90, 2003.
114. MacDonald N, Der L, Allan S, Champion P. Opioid hyperexcitability: the application of alternate opioid therapy. Pain 53:353-5, 1993.
115. Lawlor PG. Delirium and dehydration: some fluid for thought? Support Care Cancer 10:445-54, 2002.
116. Lawlor P, Pereira J, Bruera E. Dose ratios among different opioids: update on the use of the equianalgesic table. In: Portenoy RK, Bruera E, eds. Topics in palliative care. New York: Oxford University Press, 2000.
117. Colpaert FC. Drug discrimination: no evidence for tolerance to opiates. Pharmacol Rev 47:605-629, 1995.
118. Portenoy RK. Tolerance to opioid analgesics: clinical aspects. Cancer Surv 21:49-65, 1994.
119. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 62:259-74, 1995.
120. Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin North Am 91:199-21, 2007.
121. Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D- aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 187(3):165-8, 1995.
122. Lawlor P., Turner KS, Hanson J, Bruera ED. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 82:1167-73, 1998.
123. Makin MK, Ellershaw JE. Substitution of another opioid for morphine. Methadone can be used to manage neuropathic pain related to cancer. BMJ 317:81, 1998.
124. Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78:852-7, 1996.
125. Vigano A, Fan D, Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 67:115-19, 1996.
126. Crews JC, Sweeney NJ, Denson DD. Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete crosstolerance among opioid agonist analgesics. Cancer 72:2266-72, 1993.
127. Manfredi PL, Borsook D, Chandler SW, Payne R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain 70:99-101, 1997.
128. Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 19:2898-904, 2001.
129. Ripamonti C, Groff L, Brunelli C, et al. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 16:3216-21, 1998.
130. Ripamonti C, De Conno F, Groff L, et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 9:79-83, 1998.
131. Morley JS, Bridson J, Nash TP, et al. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliat Med 17:57687, 2003.
132. Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev CD 003971, 2007.
133. Mao J. Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep 10:67-70, 2006.
134. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 100:213-17, 2002.
135. Davis MP, Shaiova LA, Angst MS. When opioids cause pain. J Clin Oncol 25:4497-8, 2007.
136. Fallon M, Colvin L. Opioid-induced hyperalgesia: fact or fiction? Palliat Med 22:5-6, 2008.
137. Ross JR, Riley J, Quigley C, Welsh KI. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist 11:765-7, 2006.
138. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86:1856-66, 1999.
139. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev CD004847, 2007.
140. Cherny NI, Foley KM. Nonopioid and opioid analgesic pharmacotherapy of cancer pain. Hematol Oncol Clin North Am 10:79-102, 1996.
141. Pereira J, Lawlor P, Vigano A, et al. Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manage 22:672-8, 2001.
142. McQuay HJ, Tramer M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. Pain 68:217-27, 1996.
143. McQuay H, Carroll D, Jadad AR, et al. Anticonvulsant drugs for management of pain: a systematic review. BMJ 311:1047-52, 1995.
144. Yuen KK, Shelley M, Sze WM, et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev CD00625, 2006.
145. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev CD003474, 2005.
146. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-44, 2003.
147. Saad F, Gleason DM, Murray R, et al. A randomized, placebo- controlled trial of zoledronic acid in patients with hormone- refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-68, 2002.
148. Grond S, Zech D, Diefenbach C, et al. Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain 64:107-14, 1996.
149. Kautio AL, Haanpaa M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 35:31-9, 2008.
150. Cata JP, Weng HR, Burton AW, et al. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 8:296-306, 2007.
151. Hohmann AG. A cannabinoid pharmacotherapy for chemotherapy-evoked painful peripheral neuropathy. Pain 118:3-5, 2005.
152. Leonard GD, Wright MA, Quinn MG, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 5:116, 2005.
153. Durand JP, Alexandre J, Guillevin L, Goldwasser F. Clinical activity of venlafaxine and topiramate against oxaliplatin- induced disabling permanent neuropathy. Anticancer Drugs 16:587-91, 2005.
154. Kudel I, Edwards RR, Kozachik S, et al. Predictors and consequences of multiple persistent postmastectomy pains. J Pain Symptom Manage 34:619-27, 2007.
155. Thompson AR. Recognizing chronic postsurgical pain syndromes at the end of life. Am J Hosp Palliat Care 24:319-22, 2007.
156. Mike S, Harrison C, Coles B, et al. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev CD00524, 2006.
157. Homs MY, Gaast A, Siersema PD, et al. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev CD004063, 2006.
158. Yip D, Karapetis C, Strickland A, et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev CD002093, 2006.
159. Vogel CL, Cobleigh MA, Tripathy D, et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61(Suppl 2):37-42, 2001.
160. Jones GL, Ledger W, Bonnett TJ, et al. The impact of treatment for gynecological cancer on health-related quality of life (HRQoL): a systematic review. Am J Obstet Gynecol 194:26-42, 2006.
161. Au HJ, Mulder KE, Fields AL. Systematic review of management of colorectal cancer in elderly patients. Clin Colorectal Cancer 3:165-71, 2003.
162. Saarto T, Janes R, Tenhunen M, Kouri M. Palliative radiotherapy in the treatment of skeletal metastases. Eur J Pain 6:323-30, 2002.
163. Hoskin PJ. Radiotherapy for bone pain. Pain 63:137-9, 1995.
164. McQuay HJ, Collins SL, Carroll D, Moore RA. Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev CD001793, 2008.
165. Price P, Hoskin PJ, Easton D, et al. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 6:247-55, 1986.
166. Mithal NP, Needham PR, Hoskin PJ. Retreatment with radiotherapy for painful bone metastases. Int J Radiat Oncol Biol Phys 29:1011-14, 1994.
167. Molassiotis A, Fernadez-Ortega P, Pud D, et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655-63, 2005.
168. Davidson R, Geoghegan L, McLaughlin L, Woodward R. Psychological characteristics of cancer patients who use complementary therapies. Psychooncology 14:187-95, 2005.
169. Ernst E. Usage of complementary therapies in rheumatology: a systematic review. Clin Rheum 17:301-5, 1998.
170. Begbie SD, Kerestes ZL, Bell DR. Patterns of alternative medicine use by cancer patients. Med J Aust 165:545-8, 1996.
171. Soden K, Vincent K, Craske S, et al. A randomized controlled trial of aromatherapy massage in a hospice setting. Palliat Med 18:87-92, 2004.
172. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733-9, 1999.
173. Bruera E, Macmillan K, Kuehn N, Miller MJ. Circadian distribution of extra doses of narcotic analgesics in patients with cancerpain: a preliminary report. Pain 49:311-14, 1992.
174. Cleeland CS. Measurement of pain by subjective report. Advances in pain research and therapy, vol. 12: issues in pain measurement. New York: Raven Press, 1989, pp 391-403.
175. Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277-84, 1995.
176. Wang XS, Cleeland CS, Mendoza TR, et al. The effects of pain severity on health-related quality of life: a study of Chinese cancer patients. Cancer 86:1848-55, 1999.
177. Kurtz ME, Kurtz JC, Stommel M, et al. Predictors of physical functioning among geriatric patients with small cell or nonsmall cell lung cancer 3 months after diagnosis. Support Care Cancer 7:328-31, 1999.
178. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45:2220-4, 1980.
179. Osoba D, MacDonald N. Principles governing the use of cancer chemotherapy in palliative care. In: Doyle D, Hanks GWC, MacDonald N, eds. Oxford textbook of palliative medicine, 2nd ed. Oxford: Oxford University Press, 1998, pp 249-67.
180. Kaasa T, Loomis J, Gillis K, et al. The Edmonton Functional Assessment Tool: preliminary development and evaluation for use in palliative care. J Pain Symptom Manage 13:10-19, 1997.
181. Anderson F, Downing GM, Hill J, et al. Palliative performance scale (PPS): a new tool. J Palliat Care 12:5-11, 1996.
182. Olajide O, Hanson L, Usher BM, et al. Validation of the palliative performance scale in the acute tertiary care hospital setting. J Palliat Med 10:111-17, 2007.
183. Virik K, Glare P. Validation of the palliative performance scale for inpatients admitted to a palliative care unit in Sydney, Australia. J Pain Symptom Manage 23:455-7, 2002.
184. Heaven CM, Maguire P. The relationship between patients’ concerns and psychological distress in a hospice setting. Psychooncology 7:502-7, 1998.
185. Portenoy R., Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 3:183-9, 1994.
186. Zaza C, Baine N. Cancer pain and psychosocial factors: a critical review of the literature. J Pain Symptom Manage 24:526-42, 2002.
187. Bredart A, Didier F, Robertson C, et al. Psychological distress in cancer patients attending the European Institute of Oncology in Milan. Oncology 57:297-302, 1999.
188. Oates CT, Sloane R, Ingram SS, et al. Evaluation of agreement between physicians’ notation of ‘no evidence of disease’ (NED) and patients’ report of cancer status. Psychooncology 16:668-75, 2007.
189. Keller M, Sommerfeldt S, Fischer C, et al. Recognition of distress and psychiatric morbidity in cancer patients: a multimethod approach. Ann Oncol 15:1243-9, 2004.
190. Kristeller JL, Zumbrun CS, Schilling RF. ‘I would if I could’: how oncologists and oncology nurses address spiritual distress in cancer patients. Psychooncology 8:451-8, 1998.
191. Kaasa S, Malt U, Hagen S, et al. Psychological distress in cancer patients with advanced disease. Radiother Oncol 27:193-7, 1993.
192. Portenoy R., Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 3:183-9, 1994.
193. Cella DF, Orofiamma B, Holland JC, et al. The relationship of psychological distress, extent of disease, and performance status in patients with lung cancer. Cancer 60:1661-7, 1987.
194. Glover J, Dibble SL, Dodd MJ, Miaskowski C. Mood states of oncology outpatients: does pain make a difference? J Pain Symptom Manage 10:120-8, 1995.
195. Lloyd-Williams M, Dennis M, Taylor F. A prospective study to determine the association between physical symptoms and depression in patients with advanced cancer. Palliat Med 18:558-63, 2004.
196. Koopman C, Hermanson K, Diamond S, et al. Social support, life stress, pain and emotional adjustment to advanced breast cancer. Psychooncology 7:101-11, 1998.
197. Spiegel D, Sands S, Koopman C. Pain and depression in patients with cancer. Cancer 74:2570-8, 1994.
198. Palesh OG, Collie K, Batiuchok D, et al. A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer. Biol Psychol 75:37-44, 2007.
199. Kurtz ME, Kurtz JC, Stommel M, et al. The influence of symptoms, age, comorbidity and cancer site on physical functioning and mental health of geriatric women patients. Women Health 29:1-12, 1999.
200. Butler LD, Koopman C, Cordova MJ, et al. Psychological distress and pain significantly increase before death in metastatic breast cancer patients. Psychosom Med 65:416-26, 2003.
201. Strang P. Existential consequences of unrelieved cancer pain. Palliat Med 11:299-305, 1997.
202. Portenoy RK. Pain and quality of life: clinical issues and implications for research. Oncology 4:172-8, 1990.
203. Melzack R, Wall P. Pain mechanisms: a theory. Science 150:971-9, 1965.
204. Turk DC, Okifuji A. Assessment of patients’ reporting of pain: an integrated perspective. Lancet 353:1784-8, 1999.
205. Tope DM, Ahles TA, Silberfarb PM. Psycho-oncology: psychological well-being as one component of quality of life. Psychother Psychosom 60:129-47, 1993.
206. Chapman CR, Gavrin J. Suffering: the contributions of persistent pain. Lancet 353:2233-7, 1999.
207. Watson D, Pennebaker JW. Health complaints, stress, and distress: exploring the central role of negative affectivity. Psychol Rev 96:234-54, 1989.
208. Novy D, Berry MP, Palmer JL, et al. Somatic symptoms in patients with chronic non-cancer-related and cancer-related pain. J Pain Symptom Manage 29:603-12, 2005.
209. Koller M, Kussman J, Lorenz W, et al. Symptom reporting in cancer patients: the role of negative affect and experienced social stigma. Cancer 77:983-95, 1996.
210. Koller M, Heitmann K, Kussmann J, Lorenz W. Symptom reporting in cancer patients II: relations to social desirability, negative affect, and self-reported health behaviors. Cancer 86:1609-20, 1999.
211. Porter LS, Keefe FJ, Lipkus I, Hurwitz H. Ambivalence over emotional expression in patients with gastrointestinal cancer and their caregivers: associations with patient pain and quality of life. Pain 117:340-8, 2005.
212. Chaturvedi SK. Exploration of concerns and role of psychosocial intervention in palliative care - a study from India. Ann Acad Med Singapore 23:256-60, 1994.
213. Cassell EJ. The nature of suffering and the goals of medicine. N Engl J Med 306:639-45, 1982.
214. Dalton JA, Feuerstein M. Biobehavioral factors in cancer pain. Pain 33:137-47, 1988.
215. Cherny NI, Coyle N, Foley KM. Suffering in the advanced cancer patient: a definition and taxonomy. J Palliat Care 10:57-70, 1994.
216. Fishman B. The treatment of suffering in patients with cancer pain. Cognitive-behavioral approaches. In: Foley KM, Bonica JJ, Ventafridda V, eds. Advances in pain research and therapy, vol 16. New York: Raven Press, 1990, pp 301-16.
217. Murata H. Spiritual pain and its care in patients with terminal cancer: construction of a conceptual framework by philosophical approach. Palliat Support Care 1:15-21, 2003.
218. Chapman CR, Gavrin J. Suffering and its relationship to pain. J Palliat Care 9:5-13, 1993.
219. Wilson KG, Chochinov HM, McPherson CJ, et al. Suffering with advanced cancer. J Clin Oncol 25:1691-7, 2007.
220. Cassell EJ. Diagnosing suffering: a perspective. Ann Intern Med 131:531-4, 1999.
221. Saunders C. The philosophy of terminal care. In: Saunders C, ed. The management of terminal malignant disease, 2nd ed. Baltimore: Arnold, 1984, pp 232-41.
222. Kearney M. Mortally wounded. Stories of soul pain, death, and healing. New York: Scribner, 1996.
223. Folkman S, Lazarus RS, Dunkel-Schetter C, et al. Dynamics of a stressful encounter: cognitive appraisal, coping, and encounter outcomes. J Pers Soc Psychol 50:992-1003, 1986.
224. Lazarus RS. Coping with the stress of illness. WHO regional publications. European series. 44:11-31, 1992.
225. Barkwell DP. Ascribed meaning: a critical factor in coping and pain attenuation in patients with cancer-related pain. J Palliat Care 7:5-14, 1991.
226. Parle M, Jones B, Maguire P. Maladaptive coping and affective disorders among cancer patients. Psychol Med 26:735-44, 1996.
227. McGrath P. Creating a language for ‘spiritual pain’ through research: a beginning. Support Care Cancer 10:637-46, 2002.
228. McClain-Jacobson C, Rosenfeld B, Kosinski A, et al. Belief in an afterlife, spiritual well-being and end-of-life despair in patients with advanced cancer. Gen Hosp Psychiatry 26:484-6, 2004.
229. Breitbart W, Gibson C, Poppito SR, Berg A. Psychotherapeutic interventions at the end of life: a focus on meaning and spirituality. Can J Psychiatry 49:366-72, 2004.
230. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev 84:191-215, 1977.
231. Lin CC. Comparison of the effects of perceived self-efficacy on coping with chronic cancer pain and coping with chronic low back pain. Clin J Pain 14:303-10, 1998.
232. Syrjala KL, Chapko ME. Evidence for a biopsychosocial model of cancer treatment-related pain. Pain 61:69-79, 1995.
233. Cunningham AJ, Lockwood GA, Cunningham JA. A relationship between perceived self-efficacy and quality of life in cancer patients. Patient Educ Couns 17:71-8, 1991.
234. Bishop SR, Warr D. Coping, catastrophizing and chronic pain in breast cancer. J Behav Med 26:265-81, 2003.
235. Abraham A, Kutner JS, Beaty B. Suffering at the end of life in the setting of low physical symptom distress. J Palliat Med 9:658-65, 2006.
236. Mystakidou K, Tsilika E, Parpa E, et al. Psychological distress of patients with advanced cancer: influence and contribution of pain severity and pain interference. Cancer Nurs 29:400-5, 2006.
237. Maguire P. Barriers to psychological care of the dying. Br Med J Clin Res Ed 291:1711-13, 1985.
238. Myers LB, Vertere A. Repressors’ responses to health-related questionnaires. Br J Health Psychol 2:245-75, 1997.
239. Maguire P, Faulkner A, Booth K, et al. Helping cancer patients disclose their concerns. Eur J Cancer 32A:78-81, 1996.
240. Maguire P, Booth K, Elliott C, Jones B. Helping health professionals involved in cancer care acquire key interviewing skills - the impact of workshops. Eur J Cancer. 32A:1486-9, 1996.
241. Platt FW, Keller VF. Empathic communication: a teachable and learnable skill. J Gen Intern Med 9:222-6, 1994.
242. Beck A, Ward C, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 4:561-71, 1961.
243. Holland JC, Kash KM, Passik S, et al. A brief spiritual beliefs inventory for use in quality of life research in life-threatening illness. Psychooncology 7:460-9, 1998.
244. Zigmond AS, Snaith PR. The hospital anxiety and depression scale. Acta Psychiatr Scand 67:360-70, 1983.
245. Graves KD, Arnold SM, Love CL, et al. Distress screening in a multidisciplinary lung cancer clinic: prevalence and predictors of clinically significant distress. Lung Cancer 55:215-24, 2007.
246. Chochinov HM, Wilson KG, Enns M, Lander S. “Are you depressed?” Screening for depression in the terminally ill. Am J Psych 154:674-6, 1997.
247. Derogatis LR, Morrow GR, Fetting J, et al. The prevalence of psychiatric disorders among cancer patients. JAMA 249:751-7, 1983.
248. American Psychiatric Association. Somatoform disorders. In: Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994, pp 445-65.
249. Gureje O, Simon GE, Ustun TB, Goldberg DP. Somatization in cross-cultural perspective: a World Health Organization study in primary care. Am J Psych 154:989-95, 1997.
250. Guthrie E. Emotional disorder in chronic illness: psychotherapeutic interventions. Br J Psych 168:265-73, 1996.
251. Kirmayer LJ, Young A. Culture and somatization: clinical, epidemiological, and ethnographic perspectives Psychosom Med 60:420-30, 1998.
252. Katon W, Lin E, Von Korff M, et al. Somatization: a spectrum of severity. Am J Psych 148:34-40, 1991.
253. Lipowski ZJ. Somatization: a borderland between medicine and psychiatry. CMAJ 135:609-14, 1986.
254. Lipowski ZJ. Somatization: the concept and its clinical application. Am J Psych 145:1358-68, 1988.
255. Simon GE, Von Korff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 341:1329-35, 1999.
256. Chaturvedi SK, Maguire GP. Persistent somatization in cancer: a controlled follow-up study. J Psychosom Res 45:249-56, 1988.
257. Chaturvedi SK, Hopwood P, Maguire P. Non-organic somatic symptoms in cancer. Eur J Cancer 29A:1006-8, 1993.
258. Cleeland CS, Nakamura Y, Mendoza TR, et al. Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain 67:267-73, 1996.
259. Erbil P, Razavi D, Farvacques C, et al. Cancer patients psychological adjustment and perception of illness: cultural differences between Belgium and Turkey. Support Care Cancer 4:455-61, 1996.
260. Farooq S, Gahir MS, Okyere E, et al. Somatization: a transcultural study. J Psychosom Res 39:883-8, 1995.
261. Lin CC. Disclosure of the cancer diagnosis as it relates to the quality of pain management among patients with cancer pain in Taiwan. J Pain Symptom Manage 18:331-7, 1999.
262. Hamadeh GN, Adib SM. Cancer truth disclosure by Lebanese doctors. Soc Sci Med 47:1289-94, 1998.
263. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA 252:1905-7, 1984.
264. Bruera E, Moyano J, Seifert L, et al. The frequency of alcoholism among patients with pain due to terminal cancer. J Pain Symptom Manage 10:599-603, 1995.
265. Lawlor P., Quan H, Hanson J, Bruera E. Screening for alcohol abuse in an advanced cancer population. Support Care Cancer 8:253, 2000.
266. Gratzer D, Levitan RD, Sheldon T, et al. Lifetime rates of alcoholism in adults with anxiety, depression, or co-morbid depression/anxiety: a community survey of Ontario. J Affect Disord 79:209-15, 2004.
267. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 64:830-42, 2007.
268. American Psychiatric Association. Adjustment disorders. In: Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994, pp 623-7.
269. Velikova G, Selby PJ, Snaith PR, Kirby PG. The relationship of cancer pain to anxiety. Psychother Psychosom 63:181-4, 1995.
270. Spiegel D, Sands S, Koopman C. Pain and depression in patients with cancer. Cancer 74:2570-8, 1994.
271. Strang P. Emotional and social aspects of cancer pain. Acta Oncologica 31:323-6, 1992.
272. Hay JL, Passik SD. The cancer patient with borderline personality disorder: suggestions for symptom-focused management in the medical setting. Psychooncology 9:91-100, 2000.
273. American Psychiatric Association. Personality disorders. In: Diagnostic and statistical manual of mental disorders, 4th ed. Washington DC: American Psychiatric Association, 1994, pp 629-73.
274. Passik SD, Hay JL. Symptom control in patients with severe character pathology. In: Portenoy RK, Bruera E, eds. Topics in palliative care, vol. 3. New York: Oxford University Press, 1998, pp 213-27.